Artificial intelligence (AI) software company Lunit announced on Tuesday the integration of its PD-L1 scoring algorithm into the Guardant360 TissueNext PD-L1 test non-small cell lung cancer (NSCLC) biomarker detection.
The integrated Lunit Scope PD-L1 algorithm will augment the TissueNext test’s detection of the PD-L1 biomarker in tissue samples using an AI-based scoring system.
In a study published in the European Journal of Cancer, the TissueNext test with integrated Scope PD-L1 demonstrated more than 20% higher accuracy in detecting the PD-L1 biomarker for NSCLC than manual pathologist interpretation.
The CE-marked Scope algorithm is designed to minimize interpretation discrepancies and allow for better prediction of treatment outcomes.
"The digital pathology solution from Lunit has already demonstrated the power of AI to help improve detection of PD-L1 in certain cases of non-small cell lung cancer. We believe it has the potential to contribute much more broadly to advances in identifying cancer biomarkers and informing treatment decisions," Helmy Eltoukhy, co-CEO of Guardant Health, said in a statement.
Guardant and Lunit have been in a partnership since 2021, following Guardant’s strategic investment in Lunit.